Shuttle Pharmaceuticals Holdings, Inc. has announced the dismissal of its independent registered public accounting firm, Forvis Mazars, effective after the filing of its latest quarterly report. This decision, made by the company’s Audit Committee and Board of Directors, underscores ongoing challenges in the company's financial reporting practices.
The dismissal was officially recorded in a recent SEC filing on October 22, 2026. The company stated that Forvis Mazars' reports did not contain any adverse opinions or disclaimers regarding the financial statements for the years ended December 31, 2025, and 2024. However, they did include an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
Shuttle Pharmaceuticals, which operates in the pharmaceutical preparations sector (SIC 2834), is based in Gaithersburg, Maryland. The company is publicly traded on the Nasdaq under the ticker SHPH. The recent filing indicates that there were no disagreements between the company and Forvis Mazars concerning accounting principles or practices during the relevant periods.
However, the filing also highlighted material weaknesses in the company’s internal controls over financial reporting. These issues include inadequate oversight over accounting transactions, insufficient segregation of duties, and deficiencies in overall information technology controls. Such weaknesses raise concerns about the accuracy and reliability of the company’s financial disclosures.
The dismissal of Forvis Mazars follows a series of recent disclosures by Shuttle Pharmaceuticals regarding its financial practices. In its Quarterly Report for the fiscal quarter ended June 30, 2026, the company had already acknowledged these material weaknesses, which could potentially impact investor confidence and the company's market position.
As of now, Shuttle Pharmaceuticals has not engaged a new independent registered public accounting firm to replace Forvis Mazars. The lack of a new auditor raises questions about the company’s financial oversight moving forward and could have implications for its ability to secure future financing or partnerships.
The implications of this change may extend beyond Shuttle Pharmaceuticals. The pharmaceutical preparations industry is facing increased scrutiny over financial disclosures, especially as companies navigate complex regulatory environments and investor expectations. Competitors in this space may need to reassess their own financial reporting practices to avoid similar pitfalls.
Looking ahead, it remains to be seen how Shuttle Pharmaceuticals will address these financial reporting challenges and whether it will appoint a new auditor in the near future. The company has authorized Forvis Mazars to respond to inquiries from any successor auditor regarding the material weaknesses discussed in the filing.
The filing does not specify what actions will be taken next regarding the appointment of a new auditor or how the company plans to rectify its internal control weaknesses.